67 results about "Disease stages" patented technology

A system (100) and method is provided for performing a model-based segmentation of an anatomical structure in a medical image of a patient. The medical image (022) is accessed. Moreover, model data (162) is provided which defines a deformable model for segmenting the type of anatomical structure. The model-based segmentation of the anatomical structure is performed by adapting the deformable model to the anatomical structure in the medical image using an adaptation technique. In accordance with the present invention, performing the model based segmentation further comprises determining from patient data (042) medical information which is predictive of an appearance of the anatomical structure in the medical image, and adjusting or setting a segmentation parameter based on the medical information so as to adjust the model-based segmentation to said predicted appearance of the anatomical structure in the medical image, the segmentation parameter being a parameter of i) the deformable model or ii) the adaptation technique. Advantageously, the system and method are enabled to better cope with the inter-patient and inter-disease-stage variability in the appearance of anatomical structures.

A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immuno-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays.

Methods are provided for diagnosing and / or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of low molecular actin fragments. The assay results are used to diagnose the presence of chronic immune disease activity and / or characterize chronic immune disease activity in the subject, e.g. to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. Also provided by the subject invention are kits for practicing the methods.

The present invention relates to an in vivo equine disease model for equine herpesvirus-1 neurological disease comprising a horse having a low pre-exposure level of herpesvirus-specific CTL precursors and / or is approximately 20 years of age or older wherein the horse is experimentally infected with a neuropathogenic strain of equine herpesvirus or a mutant thereof. The invention includes a method of preparing an in vivo equine disease model for equine herpesvirus-1 neurological disease comprising obtaining a horse that possesses low pre-infection levels of EHV-1 specific CTL precursors and / or is approximately 20 years of age or older and inoculating the horse intranasally with an effective infecting amount of a neuropathogenic strain of EHV-1. A particularly preferred method involves the advanced neurological disease stage when the experimental horse presents clinical signs of myeloencephalopathy. Additionally, the invention concerns a method of quantifying the risk factors and predicting the development of clinical neurologic signs of equine herpesvirus-1 neurological disease in a horse comprising the steps of (a) determining the pre-infection CTLp frequency to be less than approximately 40 EHV-1 specific CTLp per 106 PBMC; and (b) determining the post-infection viremic load following exposure to EHV-1 to be approximately 10-fold or more over the viremic load present in horses following exposure to a non-neuropathogenic strain of EHV-1. Also described in the invention is the determination of the risk of developing the clinical neurologic signs by use of an equation y=a+bx wherein y is the peak viremic load, a=2.97, b=−0.027 and the variable x is the pre-infection CTLp frequency. Lastly, the invention deals with a new live, attenuated vaccine formulation that is effective against neurologic disease due to equine herpesvirus-1.